REPLIGEN CORP Acquisitions, Net of Cash Acquired
REPLIGEN CORP (RGEN) reported Acquisitions, Net of Cash Acquired of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-07-29
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for the quarter ending 2025-12-31 was $374.00K, a 99.32% decline year-over-year.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for the quarter ending 2025-09-30 was $0.00.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for fiscal 2025 was $70.33M, a 28.42% increase from fiscal 2024.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for fiscal 2024 was $54.77M, a 70.66% decline from fiscal 2023.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for fiscal 2023 was $186.64M.
- REPLIGEN CORP payments to acquire businesses, net of cash acquired for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | $374.00K derived: sum of 3 quarters · filed 2026-07-29 | $374.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $374.00K derived: sum of 2 quarters · filed 2026-05-06 | $374.00K derived: sum of 3 quarters · filed 2026-05-06 | $608.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $374.00K derived: sum of 2 quarters · filed 2026-02-26 | $608.00K derived: sum of 3 quarters · filed 2026-07-29 | $70.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $234.00K derived: sum of 2 quarters · filed 2026-07-29 | $69.95M 10-Q · filed 2025-11-04 | $124.72M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $69.95M 10-Q · filed 2026-07-29 | $124.72M derived: sum of 3 quarters · filed 2026-07-29 | $124.72M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $69.72M 10-Q · filed 2026-05-06 | $124.48M derived: sum of 2 quarters · filed 2026-05-06 | $124.48M derived: sum of 3 quarters · filed 2026-05-06 | $124.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $54.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $54.77M derived: sum of 2 quarters · filed 2026-02-26 | $54.77M derived: sum of 3 quarters · filed 2026-02-26 | $54.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $158.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $158.80M derived: sum of 3 quarters · filed 2026-02-26 | $158.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | $158.80M derived: sum of 2 quarters · filed 2026-02-26 | $158.54M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $158.80M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $158.54M derived: sum of 2 quarters · filed 2026-02-26 | $186.64M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$256.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $27.84M 10-Q/A · filed 2024-11-18 | ||
| 2023-06-30 | $28.10M 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-14 | $0.00 10-K · filed 2025-03-14 | |
| 2022-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | ||
| 2022-06-30 | $0.00 10-Q/A · filed 2024-11-18 | |||
| 2021-12-31 | $28.91M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $149.96M derived: sum of 2 quarters · filed 2024-11-18 | $149.96M derived: sum of 3 quarters · filed 2024-11-18 | $149.89M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $121.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $121.05M derived: sum of 2 quarters · filed 2022-11-01 | $120.98M 10-Q · filed 2022-11-01 | $267.57M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$71.00K 10-Q · filed 2022-08-02 | $146.53M derived: sum of 3 quarters · filed 2023-02-22 | |
| 2021-03-31 | -$71.00K 10-Q · filed 2022-04-27 | $146.53M derived: sum of 2 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $146.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $175.04M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $28.45M 10-Q · filed 2021-10-28 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$22.00K derived: sum of 2 quarters · filed 2022-02-17 | $182.15M 10-K · filed 2022-02-17 | |
| 2019-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $182.15M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $182.18M 10-Q · filed 2020-07-30 | |||
| 2017-09-30 | $112.94M 10-Q · filed 2018-11-01 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $8.77M 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | $8.77M 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |